Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06671613 · ClinicalTrials.gov registry record · NA

Evaluating a Fasting-mimicking Diet in Combination With Immunotherapy in Patients With Non-small Cell Lung Cancer

A NA study of NSCLC and Immunotherapy, sponsored by VA Office of Research and Development.

Recruiting
Registry status
NA
Development phase
66
Enrollment target
4
Study locations

NCT06671613 is a NA study of NSCLC and Immunotherapy that is actively recruiting participants, run by VA Office of Research and Development. The registered enrollment target is 66 participants, below the 223-participant average among 71 other NSCLC trials with a reported enrollment target (70% lower). The trial reports 4 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06671613, a NA study of NSCLC and Immunotherapy, is actively recruiting participants, sponsored by VA Office of Research and Development.

RECRUITING
Registry status
NA
Development phase
66 participants
Enrollment target
4
Study locations

Study Summary

The purpose of this study is to learn the effects of fasting on cancer cells while you get maintenance treatment.

Interventions

  • DIETARY_SUPPLEMENT FMD
  • COMBINATION_PRODUCT Regular Diet Plus FMD

Study Locations (4)

California

  • VA Long Beach Healthcare System, Long Beach, CA - Long Beach

Illinois

  • Jesse Brown VA Medical Center, Chicago, IL - Chicago

Indiana

  • Richard L. Roudebush VA Medical Center, Indianapolis, IN - Indianapolis

Missouri

  • St. Louis VA Medical Center John Cochran Division, St. Louis, MO - St Louis

Trial Details

FieldValue
Enrollment Target 66 participants
Start Date 2025-10-27
Est. Completion 2030-12-31
Phase NA

Sponsor

VA Office of Research and Development

1,668 total trials

What the Registry Record Tells You About NCT06671613

The ClinicalTrials.gov registry entry for NCT06671613 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 223-participant average among 71 other NSCLC trials with a reported enrollment target (70% lower). The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with NSCLC appearing as the primary indexed condition, and to 2 interventions - of which FMD is the first listed.

NCT06671613 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Illinois, Indiana.

Frequently Asked Questions

What is clinical trial NCT06671613 about?

NCT06671613 is a clinical study titled "Evaluating a Fasting-mimicking Diet in Combination With Immunotherapy in Patients With Non-small Cell Lung Cancer". The purpose of this study is to learn the effects of fasting on cancer cells while you get maintenance treatment.

What is the current status of trial NCT06671613?

This trial is currently recruiting. It is a NA study. The enrollment target is 66 participants. The study started on 2025-10-27. Estimated completion is 2030-12-31.

What conditions does trial NCT06671613 study?

This clinical trial studies the following conditions: NSCLC, Immunotherapy, Stage IV NSCLC, Fasting Mimicking Diet.

What interventions are being tested in trial NCT06671613?

The interventions under investigation include: FMD (DIETARY_SUPPLEMENT), Regular Diet Plus FMD (COMBINATION_PRODUCT).

Who is sponsoring clinical trial NCT06671613?

This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06671613 being conducted?

This trial has 4 study locations across California, Illinois, Indiana, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for NSCLC

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.